122 related articles for article (PubMed ID: 36382481)
21. Molecular Alterations in Thyroid Carcinoma.
Haroon Al Rasheed MR; Xu B
Surg Pathol Clin; 2019 Dec; 12(4):921-930. PubMed ID: 31672298
[TBL] [Abstract][Full Text] [Related]
22. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
[TBL] [Abstract][Full Text] [Related]
23. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Trojanowski T; Milanowski J
Brain Tumor Pathol; 2017 Jan; 34(1):36-41. PubMed ID: 28097440
[TBL] [Abstract][Full Text] [Related]
25. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
28. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
[TBL] [Abstract][Full Text] [Related]
29. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
[TBL] [Abstract][Full Text] [Related]
30. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
[TBL] [Abstract][Full Text] [Related]
31. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
32. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.
Sutcliffe P; Connock M; Shyangdan D; Court R; Kandala NB; Clarke A
Health Technol Assess; 2013 Sep; 17(42):1-274. PubMed ID: 24070110
[TBL] [Abstract][Full Text] [Related]
33. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.
Eloy C; Santos J; Soares P; Sobrinho-Simões M
Virchows Arch; 2011 Sep; 459(3):265-76. PubMed ID: 21796448
[TBL] [Abstract][Full Text] [Related]
34. Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.
Morandi L; Righi A; Maletta F; Rucci P; Pagni F; Gallo M; Rossi S; Caporali L; Sapino A; Lloyd RV; Asioli S
Endocr Relat Cancer; 2017 Feb; 24(2):107-117. PubMed ID: 28062544
[TBL] [Abstract][Full Text] [Related]
35. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
36. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
37. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
[No Abstract] [Full Text] [Related]
38. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
Griffith C; Zhang S; Mukhopadhyay S
Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
[TBL] [Abstract][Full Text] [Related]
39. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
